{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:10:04Z","timestamp":1791943804012,"version":"4.3.4"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.euf.2025.10.011","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T17:13:29Z","timestamp":1763658809000},"page":"284-296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-World Treatment Patterns and Survival in Metastatic Castration-resistant Prostate Cancer: A Systematic Review of Observational Studies"],"prefix":"10.1016","volume":"12","author":[{"given":"Amit D.","family":"Raval","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5805-3823","authenticated-orcid":false,"given":"Viji","family":"Queen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Quintero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.10.011_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euf.2025.10.011_b0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1240864","article-title":"Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews","volume":"13","author":"Leaning","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.euf.2025.10.011_b0015","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3390\/biomedicines10030689","article-title":"Definition of castrate resistant prostate cancer: new insights","volume":"10","author":"Morote","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.euf.2025.10.011_b0020","unstructured":"ScienceDirect Topics. Castration resistant prostate cancer \u2013 an overview. https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/castration-resistant-prostate-cancer#definition."},{"key":"10.1016\/j.euf.2025.10.011_b0025","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","article-title":"Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States","volume":"18","author":"George","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euf.2025.10.011_b0030","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41391-023-00725-8","article-title":"Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate Cancer (mCRPC) in the US Medicare population","volume":"27","author":"Freedland","year":"2024","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euf.2025.10.011_b0035","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1093\/oncolo\/oyad046","article-title":"Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer: results from an international study","volume":"28","author":"Barata","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.euf.2025.10.011_b0040","unstructured":"National Cancer Institute. Pembrolizumab approved for tumors with specific genetic features. 2017. https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2017\/fda-pembrolizumab-genetic-features."},{"key":"10.1016\/j.euf.2025.10.011_b0045","first-page":"622","article-title":"The treatment of metastatic, hormone-sensitive prostatic carcinoma","volume":"119","author":"Merseburger","year":"2022","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.euf.2025.10.011_b0050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11864-019-0668-8","article-title":"Management of metastatic hormone-sensitive prostate cancer (mHSPC): an evolving treatment paradigm","volume":"20","author":"Weiner","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.euf.2025.10.011_b0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.10.011_b0060","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.10.011_b0065","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.10.011_b0070","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.10.011_b0075","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.10.011_b0080","doi-asserted-by":"crossref","first-page":"350","DOI":"10.14740\/wjon1476","article-title":"Treatment patterns among patients with advanced prostate cancer in Brazil: an analysis of a private healthcare system database","volume":"13","author":"Fontes","year":"2022","journal-title":"World J Oncol"},{"key":"10.1016\/j.euf.2025.10.011_b0085","doi-asserted-by":"crossref","first-page":"1.e1","DOI":"10.1016\/j.urolonc.2019.09.027","article-title":"Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer","volume":"38","author":"Halwani","year":"2020","journal-title":"Urol Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euf.2025.10.011_b0090","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1200\/JCO.2022.40.6_suppl.252","article-title":"Real-world management of metastatic castration-resistant prostate cancer (mCRPC): a national multicenter cohort study","volume":"40","author":"Lavallee","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.10.011_b0095","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","article-title":"Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes","volume":"35","author":"Olmos","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2025.10.011_b0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.euf.2025.10.011_b0105","doi-asserted-by":"crossref","first-page":"S366","DOI":"10.1016\/j.jval.2022.09.1815","article-title":"MSR84 Training models for machine-enabled systematic literature reviews: do large datasets always give better results?","volume":"25","author":"Abogunrin","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.euf.2025.10.011_b0110","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1016\/j.jval.2023.03.1619","article-title":"MSR84 How can explainable artificial intelligence accelerate the systematic literature review process?","volume":"26","author":"Abogunrin","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.euf.2025.10.011_b0115","unstructured":"CapeStart. CapeStart debuts MadeAi\u2122, its GenAI-enabled platform. Press release; November 18, 2024. https:\/\/capestart.com\/cs-press-release\/capestart-debuts-madeai-its-genai-enabled-platform-for-life-sciences-that-transforms-literature-review-and-other-applications-2\/."},{"key":"10.1016\/j.euf.2025.10.011_b0120","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2021"},{"issue":"16 Suppl","key":"10.1016\/j.euf.2025.10.011_b0125","article-title":"Real-world treatment patterns in the U.S. and trends pre-post CARD trial among patients with metastatic castration-resistant prostate cancer","volume":"40","author":"Ghantoji","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.10.011_b0130","doi-asserted-by":"crossref","first-page":"S988","DOI":"10.1016\/j.annonc.2023.09.2772","article-title":"1824P treatment patterns among novel hormonal therapy-experienced patients with metastatic castration-resistant prostate cancer","volume":"34","author":"Narayan","year":"2023","journal-title":"Ann Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.euf.2025.10.011_b0135","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1200\/JCO.2024.42.4_suppl.55","article-title":"Real-world treatment (Tx) sequences and time to discontinuation (rwTTD) in the first-line (1L) metastatic castration-resistant prostate cancer (mCRPC) setting","volume":"42","author":"Nash Smyth","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.10.011_b0140","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","article-title":"Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors","volume":"38","author":"Shore","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.euf.2025.10.011_b0145","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/13696998.2024.2303890","article-title":"Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation","volume":"27","author":"Kaye","year":"2024","journal-title":"J Med Econ"},{"key":"10.1016\/j.euf.2025.10.011_b0150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/j.seminoncol.2023.03.001","article-title":"Tumor testing and treatment patterns in veterans with metastatic castration-resistant prostate cancer","volume":"50","author":"Hung","year":"2023","journal-title":"Semin Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.euf.2025.10.011_b0155","article-title":"MP29-05 treatment pattern and health-related quality of life (HRQoL) of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US)","volume":"209","author":"Shore","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.10.011_b0160","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.clgc.2023.04.014","article-title":"Treatment patterns, clinical outcomes, health care resource utilization and costs in older patients with metastatic castration-resistant prostate cancer in the United States: an analysis of SEER-medicare data","volume":"21","author":"Swami","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"6 Suppl","key":"10.1016\/j.euf.2025.10.011_b0165","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1200\/JCO.2022.40.6_suppl.049","article-title":"Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer (mCRPC) in the US","volume":"40","author":"Malangone-Monaco","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.10.011_b0170","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00562","article-title":"Real-world overall survival and treatment patterns by PTEN status in metastatic castration-resistant prostate cancer","author":"Gupta","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.euf.2025.10.011_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102080","article-title":"Treatment patterns and clinical outcomes among patients with metastatic prostate cancer harboring homologous recombination repair mutations","volume":"22","author":"Bobbili","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"4 Suppl","key":"10.1016\/j.euf.2025.10.011_b0180","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.2024.42.4_suppl.52","article-title":"Real-world treatment patterns in patients with BRCA 1\/2-positive (BRCA+) metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy","volume":"42","author":"Bilen","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euf.2025.10.011_b0185","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1200\/JCO.2023.41.6_suppl.80","article-title":"Time-to-next treatment (TTNT) and overall survival (OS) among homologous recombination repair (HRR) positive and HRR negative patients with metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy","volume":"41","author":"Bilen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euf.2025.10.011_b0190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1200\/JCO.2023.41.6_suppl.97","article-title":"The impact of homologous recombination repair (HRR) gene mutation status on treatment (tx) patterns and clinical outcomes among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US)","volume":"41","author":"Barata","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.euf.2025.10.011_b0195","doi-asserted-by":"crossref","first-page":"146.e13","DOI":"10.1016\/j.urolonc.2022.11.019","article-title":"A real-world retrospective analysis of the management of metastatic castrate-resistant prostate cancer in Ontario, Canada from 2010\u20132018","volume":"41","author":"Moldaver","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.10.011_b0200","doi-asserted-by":"crossref","first-page":"192.e1","DOI":"10.1016\/j.urolonc.2022.01.009","article-title":"Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada","volume":"40","author":"Shayegan","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.10.011_b0205","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1007\/s12325-022-02073-w","article-title":"Real-world treatment patterns in metastatic castration-resistant prostate cancer across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan","volume":"39","author":"Leith","year":"2022","journal-title":"Adv Ther"},{"issue":"Suppl 1","key":"10.1016\/j.euf.2025.10.011_b0210","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1016\/S2666-1683(23)01398-8","article-title":"P101 \u2013 Treatment (tx) patterns and outcomes in the real world (rw) among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in Europe","volume":"57","author":"Castro","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euf.2025.10.011_b0215","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11523-020-00720-2","article-title":"Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the Prostate Cancer Registry","volume":"15","author":"Chowdhury","year":"2020","journal-title":"Targ Oncol"},{"key":"10.1016\/j.euf.2025.10.011_b0220","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.euros.2022.08.018","article-title":"Real-world treatment sequencing in patients with metastatic castration-resistant prostate cancer: results from the prospective, international, observational Prostate Cancer Registry","volume":"45","author":"Bjartell","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euf.2025.10.011_b0225","doi-asserted-by":"crossref","DOI":"10.21037\/tcr-22-375","article-title":"Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancer","volume":"11","author":"Nishimoto","year":"2022","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.euf.2025.10.011_b0230","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1002\/cam4.5333","article-title":"The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: the multi-institutional observational ZENSHIN study","volume":"12","author":"Uemura","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.euf.2025.10.011_b0235","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bju.14980","article-title":"United in Fight against prOstate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia","volume":"125","author":"Uemura","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.10.011_b0240","doi-asserted-by":"crossref","first-page":"78","DOI":"10.17650\/1726-9776-2019-15-3-78-88","article-title":"The national registry of treatment regimens in patients with metastatic castration-resistant prostate cancer in the Russian Federation","volume":"15","author":"Karyakin","year":"2019","journal-title":"Cancer Urol"},{"key":"10.1016\/j.euf.2025.10.011_b0245","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/bco2.129","article-title":"Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer","volume":"3","author":"Anton","year":"2022","journal-title":"BJUI Compass"},{"key":"10.1016\/j.euf.2025.10.011_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2023.101621","article-title":"Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: analysis of an Australian real-world cohort","volume":"14","author":"Fernando","year":"2023","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.euf.2025.10.011_b0255","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/bju.15364","article-title":"Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer","volume":"128","author":"Kelly","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.10.011_b0260","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/cncr.33487","article-title":"Differential treatment outcomes in BRCA1\/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer","volume":"127","author":"Kwon","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2025.10.011_b0265","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41391-021-00487-1","article-title":"Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD","volume":"26","author":"de Wit","year":"2023","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euf.2025.10.011_b0270","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ejca.2021.06.005","article-title":"Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer \u2013 an Australian multi-centre observational study","volume":"157","author":"Anton","year":"2021","journal-title":"Eur J Cancer"},{"issue":"5 Suppl","key":"10.1016\/j.euf.2025.10.011_b0275","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2025.43.5_suppl.74","article-title":"Real-world treatment patterns in patients diagnosed with metastatic castration-resistant prostate cancer in the US, 2018\u20132023","volume":"43","author":"Efstathiou","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5 Suppl","key":"10.1016\/j.euf.2025.10.011_b0280","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.2025.43.5_suppl.75","article-title":"Treatment (Rx) patterns and attrition rates in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"43","author":"Gebrael","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5 Suppl","key":"10.1016\/j.euf.2025.10.011_b0285","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1200\/JCO.2025.43.5_suppl.99","article-title":"Real-world treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC) who previously progressed from metastatic hormone-sensitive prostate cancer (mHSPC) between 2020 to 2023 in the United States","volume":"43","author":"Raval","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.euf.2025.10.011_b0290","article-title":"Real-world treatment patterns, sequences, and outcomes in patients with mCRPC in US urology clinics","volume":"43","author":"Orji","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5 Suppl","key":"10.1016\/j.euf.2025.10.011_b0295","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.2025.43.5_suppl.59","article-title":"Real-world treatment patterns and outcomes in advanced prostate cancer: a cohort study using the prostate cancer disease observation (PRECISION) data platform","volume":"43","author":"Heath","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.10.011_b0300","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/14796694.2025.2470616","article-title":"Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe","volume":"21","author":"Castro","year":"2025","journal-title":"Future Oncol"},{"key":"10.1016\/j.euf.2025.10.011_b0305","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2340\/1651-226X.2025.42173","article-title":"Real-world treatment patterns and survival outcomes in men with metastatic castration-resistant prostate cancer in Finland: a national, population-based cohort study","volume":"64","author":"Rannikko","year":"2025","journal-title":"Acta Oncol"},{"key":"10.1016\/j.euf.2025.10.011_b0310","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1111\/jgs.19045","article-title":"Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real-world setting","volume":"72","author":"Wenzel","year":"2024","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.euf.2025.10.011_b0315","doi-asserted-by":"crossref","first-page":"S267","DOI":"10.1016\/j.jval.2024.10.1377","article-title":"EPH253\u2003Retrospective study of treatment patterns and patient characteristics of patients with prostate cancer treatment in Germany according to castration resistance and metastatic status","volume":"27","author":"Klein","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.euf.2025.10.011_b0320","doi-asserted-by":"crossref","first-page":"S1539","DOI":"10.1016\/j.annonc.2024.10.379","article-title":"360P\u2003Real-world treatment and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC): REMPRO-Middle East and Africa (MEA)","volume":"35","author":"Husseiny","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2025.10.011_b0325","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial\u2014FIRSTANA","volume":"35","author":"Oudard","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.10.011_b0330","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO-25-00007","article-title":"Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline update","volume":"43","author":"Garje","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.10.011_b0335","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/annonc\/mdt138","article-title":"Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide","volume":"24","author":"Noonan","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2025.10.011_b0340","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.10.011_b0345","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.10.011_b0350","unstructured":"American Urological Association. Advanced prostate cancer: AUA\/SUO guideline. Linthicum, MD: American Urological Association; 2023. https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/advanced-prostate-cancer."},{"key":"10.1016\/j.euf.2025.10.011_b0355","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925002974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925002974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T10:59:36Z","timestamp":1773745176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925002974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2405456925002974"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.10.011","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Treatment Patterns and Survival in Metastatic Castration-resistant Prostate Cancer: A Systematic Review of Observational Studies","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}